SEARCH

SEARCH BY CITATION

References

  • 1
    Hammer SM, Katzenstein DA, Hughes MD et al. A Trial Comparing Nucleoside Monotherapy with Combination Therapy in HIV-Infected Adults with CD4 Cell Counts from 200 to 500 per Cubic Millimeter. NEJM 1996; 335: 10811090.
  • 2
    Hammer SM, Squires KE, Hughes MD et al. A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less. NEJM 1997; 337: 725733.
  • 3
    Wood E, Montaner JSG, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS. Prevalence and Correlates of Untreated Human Immunodeficiency Virus Type 1 Infection among Persons Who Have Died in the Era of Modern Antiretroviral Therapy. J Infect Dis 2003; 188: 11641170.
  • 4
    Bruce RD, Altice FL. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21: 149179.
  • 5
    Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the Century: an epidemic in transition. Am J Public Health 2001; 91: 10601068.
  • 6
    Mathers B, Degenhardt L, Phillips B et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 17331745.
  • 7
    Paterson DL, Sindells S, Mohr J et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Ann Intern Med 2000; 133: 2130.
  • 8
    Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 2003; 362: 20022011.
  • 9
    Stein MD, Rich JD, Maksad J et al. Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse 2000; 26: 195205.
  • 10
    Kerr T, Palepu A, Barness G et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. AVT 2004; 9: 407414.
  • 11
    Liu H, Longshore D, Williams JK et al. Substance abuse and medication adherence among HIV-positive women with histories of child sexual abuse. AIDS Behav 2006; 10: 279286.
  • 12
    Arnsten JH, Li X, Mizuno Y et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. JAIDS 2007; 46 (Suppl. 2): S64S71.
  • 13
    Carrieri MP, Chesney MA, Spire B et al. Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. IJBM 2003; 10: 114.
  • 14
    Gordillo V, del Amo J. Soriano V and Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS 1999; 13: 17631769.
  • 15
    Palepu A, Tyndall MW, Joy R et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188194.
  • 16
    Strathdee SA, Palepu A, Cornelisse PGA et al. Barriers to Use of Free Antiretroviral Therapy in Injection Drug Users. JAMA 1998; 280: 547549.
  • 17
    Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JSG. Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 10[9] cells/L. Ann Intern Med 2003; 139: 810816.
  • 18
    Wood E, Hogg RS, Lima VD et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300: 550554.
  • 19
    Hogg RS, Heath K, Bangsberg D et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 2002; 16: 10511058.
  • 20
    d'ArminioMonforte A, Lepri AC, Rezza G et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS 2000; 14: 499507.
  • 21
    Wood E, Montaner JSG, Yip B et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ 2003; 169: 656661.
  • 22
    Palepu A, Yip B, Miller C et al. Factors associated with the response to antiretroviral therapy among HIV-infected patietns with and without a history of injection drug use. AIDS 2001; 15: 423424.
  • 23
    Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. JAIDS 2000; 23: 360361.
  • 24
    Hogg RS, Heath K, Bangsberg D et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16: 10511058.
  • 25
    WHO. World Health Organization, Child and Adolescent Health. Regional Office for South-East Asia, WHO, 2011.
  • 26
    Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003; 139: 810816.
  • 27
    Maldonado G, Grenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923936.
  • 28
    Lima V, Fernandes K, Rachlis B, Druyts E, Montaner J, Hogg R. Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients. Soc Sci Med 2009; 68: 10441049.
  • 29
    Milloy M-J, Kerr T, Buxton J et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis 2011; 203: 12151221.
  • 30
    Bouhnik A-D, Chesney M, Carrieri P et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. JAIDS 2002; 31: S149153.
  • 31
    Celentano DD, Vlahov D, Cohn S, Shadle VM, Olugbenga O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998; 280: 544546.
  • 32
    Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 2000: S171S1S6.
  • 33
    Ortego C, Huedo-Medina T, Llorca J et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav 2011; 15: 13811396.
  • 34
    Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav 2010; 14: 731747.
  • 35
    Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 2011; 5: 357367.
  • 36
    Atkinson MJ, Petrozzino JJ. An evidence-based review of treatment-related determinants of patients’ nonadherence to HIV medications. AIDS Patient Care STDS 2009; 23: 903914.
  • 37
    Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switchign from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005; 6: 185190.
  • 38
    Krusi A, Milloy M-J, Kerr T et al. Ongoing drug use and outcomes from highly active antiretroviral therapy among injection drug users in a Canadian setting. Antivir Ther 2010; 15: 789796.
  • 39
    Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JSG. Adherence to triple therapy and viral load response. JAIDS 2000; 23: 360361.
  • 40
    Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction 2008; 103: 12421257.